4-thiocarbamoylphenyl esters of 2-(4-oxophenyl)-phenylpropionic acid for treatment of pain associated with chronic pelvic pain syndrome of urinary system
By using ketoprofen derivative ATB-352, which is partially covalently linked to hydrogen sulfide release, the problem of gastrointestinal side effects and poor analgesic effect of NSAID drugs in the treatment of UCPPS is solved, and the interstitial bladder is achieved Effective relief of inflammation and pelvic pain and improvement of bladder function.
Patent Information
- Application Number
- CN202280095370.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2022-02-28
- Publication Date
- 2024-12-06
AI Technical Summary
When treating chronic pelvic pain syndrome (UCPPS), existing NSAID drugs have gastrointestinal side effects and the analgesic effect is not long-lasting enough, making it difficult to effectively relieve interstitial cystitis and pelvic pain.
4-thiocarbamoylphenyl ester (ATB-352) of ketoprofen derivative covalently linked to hydrogen sulfide (H2S) release moiety, Compounds can relieve bladder inflammation and pelvic pain, with higher gastrointestinal safety and analgesic effects.
ATB-352 significantly relieves interstitial cystitis and pelvic pain in mouse models, improves bladder contraction function, and reduces ketoprofen-induced gastric mucosal damage, showing higher analgesic efficacy and better Gastrointestinal safety.
Smart Images

Figure CN119095591A_ABST
Abstract
Description
Technical Field
[0001] The present application relates to a method for treating or preventing pain associated with urinary chronic pelvic pain syndrome (UCPPS) using 2-(4-oxophenyl)-phenylpropionic acid 4-thiocarbamoylphenyl ester or a pharmaceutically acceptable salt, prodrug and / or solvate thereof. UCPPS includes interstitial cystitis / bladder pain syndrome (IC / BPS) and chronic prostatitis / chronic pelvic pain syndrome (CP / CPPS). Background Art
[0002] NSAIDs, as well as opioids, anticonvulsants, and antimigraine drugs (e.g., 5-HT receptor agonists and ergot derivatives), are commonly used to treat acute and chronic pain. In clinical pharmacology, the use of nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g., ketoprofen) is known to be associated with a variety of gastrointestinal (GI) side effects, including mild or severe dyspepsia symptoms, development of gastric or duodenal ulcers, bleeding, perforation, and other conditions (Rusell RI, 2001). Among them, NSAIDs are used to treat chronic inflammation in patients with rheumatoid arthritis, however, they often induce gastritis (Bindu S et al., 2020). One of the most important mechanisms by which NSAIDs induce gastrointestinal damage includes, but is not limited to, inhibiting cyclooxygenase (COX)-1 or COX-2 to produce gastroprotective prostaglandins (PGs), such as PGE2 (Bindu S et al., 2020, Glowacka et al., 2020). These drugs are usually short-acting, so repeated administration is required. Therefore, more effective analgesics are needed to treat pain. For example, urological chronic pelvic pain syndrome (UCPPS) is a challenging pain disorder that encompasses interstitial cystitis / bladder pain syndrome (IC / BPS) and chronic prostatitis / chronic pelvic pain syndrome (CP / CPPS). People with UCPPS often experience pain in the pelvic region, which can cause significant discomfort and disability.
[0003] Hydrogen sulfide (H2S) is produced by any cell type, including in the gastrointestinal tract, where it is found to contribute to gastrointestinal mucosal defense and ulcer healing. It is an endogenous antioxidant gas mediator that has been shown to participate in digestive system physiology, accelerate gastric ulcer healing, and protect the gastrointestinal tract from damage caused by stress, ischemia / reperfusion, and drugs (including NSAIDs) (Lasheen NN et al., 2019, Sun H., et al 2020; Wallace JL, et al. 2017).
[0004] US 8,541,398 discloses NSAID derivatives covalently linked to H2S releasing moieties, and finds that the anti-inflammatory effects of various NSAIDs are significantly enhanced when covalently linked to H2S releasing moieties, or when using H2S releasing moieties to form NSAID salts. In addition, US 8,541,398 discloses that these NSAID derivatives covalently linked to H2S releasing moieties have potent anti-inflammatory properties and do not cause gastrointestinal toxicity. Among the many NSAID derivatives covalently linked to H2S releasing moieties, US 8,541,398 discloses a ketoprofen derivative that releases hydrogen sulfide, the chemical name of which is 2-(4-oxophenyl)-phenylpropionic acid 4-thiocarbamoylphenyl ester, sometimes also referred to as ATB-352 (Antibe Therapeutics Inc., Toronto, Canada). ATB-352 has been shown to be more potent and effective than its parent drug against periodontitis, an inflammatory disease (Gugliadola et al., 2018), and has a higher gastrointestinal safety profile than ketoprofen (Glowacka et al., 2022). ATB-352 has also been shown to be more effective than ketoprofen in a mouse surgical incision pain model (Costa et al., 2020). SUMMARY OF THE INVENTION
[0006] Applicants have demonstrated that the compound of formula I, which is a NSAID derivative covalently linked to a H2S-releasing moiety, wherein the NSAID is ketoprofen and the H2S-releasing moiety is 4-hydroxythiobenzamide (TBZ), sometimes referred to as ATB-352, can reduce bladder inflammation and pain associated with urinary chronic pelvic pain syndrome.
[0007] Thus, the present application includes a method of treating pain associated with urinary chronic pelvic pain syndrome (UCPPS) in an individual in need thereof, comprising administering to the individual an effective amount of a compound of formula I,
[0008]
[0009] or a pharmaceutically acceptable salt, prodrug and / or solvate thereof.
[0010] In certain embodiments, the pain associated with UCPPS is selected from one or more of visceral pain, neuropathic pain, neuralgia, allodynia, causalgia, hyperalgesia, hyperesthesia, hyperalgesia, and neuropathy secondary to surgery.
[0011] In certain embodiments, the pain associated with UCPPS is acute pain associated with UCPPS.
[0012] The present application also includes a method of treating urinary chronic pelvic pain syndrome (UCPPS) in an individual in need thereof, comprising administering to the individual an effective amount of a compound of formula I,
[0013]
[0014] or a pharmaceutically acceptable salt, prodrug and / or solvate thereof.
[0015] The present application also includes a method of treating one or more symptoms associated with urinary chronic pelvic pain syndrome (UCPPS) in an individual in need thereof, comprising administering to the individual an effective amount of a compound of formula I,
[0016]
[0017] or a pharmaceutically acceptable salt, prodrug and / or solvate thereof.
[0018] The present application also includes a method of treating bladder inflammation in an individual in need thereof, comprising administering to the individual an effective amount of a compound of formula I,
[0019]
[0020] or a pharmaceutically acceptable salt, prodrug and / or solvate thereof.
[0021] The present application also includes a method of increasing bladder contraction and relaxation in an individual in need thereof, comprising administering to the individual an effective amount of a compound of formula I,
[0022]
[0023] or a pharmaceutically acceptable salt, prodrug and / or solvate thereof.
[0024] The present application also includes a method of treating acute pain in an individual in need thereof, comprising administering to the individual an effective amount of a compound of formula I,
[0025]
[0026] or a pharmaceutically acceptable salt, prodrug and / or solvate thereof.
[0027] In certain embodiments, UCPPS include interstitial cystitis / bladder pain syndrome (IC / BPS) and chronic prostatitis / chronic pelvic pain syndrome (CP / CPPS).
[0028] In certain embodiments, the compound of Formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof is formulated into a pharmaceutical composition comprising the compound of Formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof and one or more pharmaceutically acceptable carriers.
[0029] According to the following detailed description, other features and advantages of the present application become apparent. However, it should be understood that the detailed description and specific examples, although indicating the embodiments of the present application, are given only by way of illustration. The scope of the claims should not be limited by these embodiments; on the contrary, they should be given the broadest interpretation consistent with the entire specification. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Embodiments of the present application will now be described in more detail with reference to the accompanying drawings, in which:
[0031] Figure 1 is a graph showing the comparative analgesic effect of the compound of formula I (ATB-352) and ketoprofen in a mouse visceral pair model (cyclophosphamide (CYP)-induced interstitial cystitis). 21 h after induction of cystitis, mice were treated orally with the compound of formula I (4.6, 15, 46 or 77 mg kg'), equimolar doses of ketoprofen (3, 10, 50 mg kg') or vehicle (CMC 0.5%). Data are expressed as the area under the curve for the interval of 21 to 24 hours after treatment with the test compound. Data are expressed as mean ± SEM (n = 5-7). *P < 0.05, relative to the vehicle. #P < 0.05, relative to the CYP group, and expP < 0.001, relative to equimolar doses of ketoprofen. One-way ANOVA followed by Tukey's test.
[0032] Figure 2 Ketoprofen induced hemorrhagic lesions in the gastric mucosa, while the compound of formula I (ATB-352) did not. -1 ), compound of formula I (77 mg kg -1 ) or ketoprofen (50 mg kg -1 ) 3 hours later, using computerized area measurement software Assessment of the area of gastric hemorrhagic lesions (mm 2 ). (1) Compared with the group of compound of formula I, P<0.05 (one-way ANOVA followed by Tukey test).
[0033] Figure 3Figure 1 shows the comparative effects of the compound of formula I (ATB-352) and ketoprofen on reversing the CYP-induced decrease in bladder contractility in response to KCl and CCh. (A) shows the contractile response to KCl (80 mM), (B) shows the solvent, CYP, compound of formula I (4.6, 15, 46 or 77 mg kg -1 ) and ketoprofen (3, 10, 30, or 50 mg kg -1 ) group. Data are expressed as mean ± SEM (n = 4-7). *P < 0.05, relative to vehicle. #P < 0.05, relative to CYP. ##P < 0.001, relative to vehicle (A and B: one-way ANOVA followed by Tukey's test). DETAILED DESCRIPTION OF THE INVENTION
[0035] I. Definitions
[0036] Unless otherwise stated, the definitions and embodiments described in this section and elsewhere are intended to apply to all embodiments and aspects of the application described herein as understood by one skilled in the art.
[0037] In understanding the scope of the present application, the term "comprising" and its derivatives used herein are intended to be open terms, which specify the presence of the features, elements, components, groups, wholes and / or steps, but do not exclude the presence of other unspecified features, elements, components, groups, wholes and / or steps. The foregoing also applies to words with similar meanings, such as the terms "including", "having" and their derivatives.
[0038] As used herein, the term "consisting of" and its derivatives are intended to serve as closed terms that specify the presence of stated features, elements, components, groups, integers and / or steps, but exclude the presence of other unstated features, elements, components, groups, integers and / or steps.
[0039] As used herein, the term "consisting essentially of" is intended to specify the presence of stated features, elements, components, groups, integers and / or steps, as well as the presence of those features, elements, components, groups, integers and / or steps that do not materially affect the basic and / or novel properties of the features, elements, components, groups, integers and / or steps.
[0040] The degree terms used herein, such as "substantially", "approximately" and "about", mean that there is a reasonable amount of deviation of the modified term so that the end result will not be significantly changed. These degree terms should be interpreted as including a deviation of at least ± 5% of the modified term, provided that such deviation does not negate the meaning of the word it modifies.
[0041] As used in this application, the singular forms "a," "an," and "the" include plural referents unless the content clearly dictates otherwise.
[0042] In embodiments comprising an "additional" or "second" component, the second component as used herein is chemically different from the other components or the first component. The "third" component is different from the other components, the first component and the second component, and further listed or "additional" components are also different.
[0043] The term "and / or" used herein means that the listed items exist or are used alone or in combination. In fact, the term means that "at least one" or "one or more" of the listed items are used or exist.
[0044] As used herein, the term "compound of formula I" or "ATB-352" refers to a compound having the following chemical name: 2-(4-oxophenyl)-phenylpropionic acid 4-thiocarbamoylphenyl ester, and having the chemical formula:
[0045]
[0046] As used herein, the term "ketoprofen" refers to a compound having the following chemical name: m-benzoylhydratropic acid or 2-(4-benzoylphenyl)propionic acid, and having the chemical formula:
[0047]
[0048] The term "pharmaceutically acceptable salt" refers to an acid addition salt or a base addition salt that is suitable or compatible with the treatment of the subject.
[0049] Acid addition salts suitable for or compatible with the treatment of an individual are any non-toxic organic or inorganic acid addition salts of any basic compound.
[0050] A base addition salt suitable for or compatible with the treatment of an individual is any non-toxic organic or inorganic base addition salt of any acidic compound.
[0051] As used herein, the term "solvate" refers to a compound or a salt of a compound in which molecules of a suitable solvent are incorporated into the crystal lattice. Suitable solvents are physiologically tolerable at the doses administered.
[0052] As used herein, the term "prodrug" refers to a compound or salt of a compound that is converted to an active drug after administration.
[0053] As used herein, the term "administering" refers to administering a therapeutically effective amount of a compound or a pharmaceutically acceptable salt, prodrug and / or solvate thereof, or a composition comprising a compound or a pharmaceutically acceptable salt, prodrug and / or solvate thereof, to cells in cell culture or an individual.
[0054] The terms "effective amount" and "therapeutically effective amount" as used herein refer to an amount of a compound of Formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof, or a composition comprising a compound of Formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof, which is effective at dosages and for periods of time necessary to achieve the desired results, including therapeutic and preventive results.
[0055] As used herein, the term "subject" includes all members of the animal kingdom, including mammals, and appropriately refers to humans. Thus, the methods and uses of the present application are applicable to both human therapy and veterinary applications.
[0056] As used herein, the term "pharmaceutical composition" refers to a composition of matter intended for pharmaceutical use.
[0057] The term "pharmaceutically acceptable" means compatible with the treatment of the subject.
[0058] As used herein, the term "parenteral" refers to entry or administration into the body other than through the gastrointestinal tract.
[0059] The terms "treatment", "processing" and "therapy" used herein, as well known in the art, refer to methods for obtaining beneficial or desired results (including clinical results). Examples of beneficial or desired results include, but are not limited to, reducing the extent of the disease, stabilizing the disease state (i.e., not worsening), preventing the spread of the disease, delaying or slowing the progression of the disease, improving or alleviating the disease state, and alleviating (whether partially or completely), whether detectable or undetectable reduction in disease recurrence. "Treatment", "processing" and "therapy" can also mean extending the survival period compared to the expected survival period if not receiving treatment. "Treatment", "processing" and "therapy" used herein also include preventive treatment.
[0060] By "alleviating" a disease, disorder or condition, it is meant that the extent and / or undesirable clinical manifestations of the disease, disorder or condition are lessened and / or the time course of progression is slowed or prolonged, as compared to not treating the disorder.
[0061] The terms "prevent" or "prevention" or their synonyms refer to reducing the risk or probability of a patient developing a disease, disorder or condition or exhibiting symptoms associated with a disease, disorder or condition.
[0062] As used herein, the term "treating pain associated with urinary chronic pelvic pain syndrome" refers to any detectable reduction in pain associated with urinary chronic pelvic pain syndrome, such as a reduction in the sensation or duration of pain associated with urinary chronic pelvic pain syndrome, following administration or use of a compound, compared to a situation that is otherwise the same except that the compound has not been administered or used.
[0063] As used herein, the term "treating pain associated with IC / BPS" refers to any detectable reduction in pain associated with IC / BPS following administration or use of a compound, such as a reduction in the sensation or duration of pain associated with IC / BPS, compared to an otherwise identical situation except that the compound was not administered or used.
[0064] As used herein, the term "treating pain associated with chronic prostatitis / chronic pelvic pain syndrome (CP / CPPS)" refers to any detectable reduction in pain associated with CP / CPPS, such as a reduction in the sensation or duration of pain associated with CP / CPPS, following administration or use of a compound, compared to a situation that is otherwise identical except that the compound has not been administered or used.
[0065] As used herein, the term "urinary chronic pelvic pain syndrome" or "UCPPS" refers to a chronic pain condition in the pelvis, prostate, bladder, and / or genitals, often with urinary frequency and urgency. UCPPS includes interstitial cystitis / bladder pain syndrome and chronic prostatitis / chronic pelvic pain syndrome.
[0066] As used herein, the term "interstitial cystitis / bladder pain syndrome" or "IC / BPS" refers to persistent or recurring chronic pelvic pain, pressure, or discomfort felt as being related to the bladder and accompanied by at least one other urinary symptom, such as urinary urgency or frequency.
[0067] As used herein, the term "chronic prostatitis / chronic pelvic pain syndrome" or "CP / CPPS" refers to long-standing pelvic pain and lower urinary tract symptoms (LUTS) without evidence of bacterial infection.
[0068] As used herein, the term "lower urinary tract symptoms" or "LUTS" refers to a group of clinical symptoms involving the bladder, urethral sphincter, urethra, and prostate in men.
[0069] The term "pain associated with urinary chronic pelvic pain syndrome" refers to pain caused directly or indirectly by or associated with urinary chronic pelvic pain syndrome.
[0070] The term "pain associated with IC / bladder pain syndrome" refers to pain caused directly or indirectly by IC / bladder pain syndrome.
[0071] The term "pain associated with chronic prostatitis / chronic pelvic pain syndrome" refers to pain caused directly or indirectly by chronic prostatitis / chronic pelvic pain syndrome.
[0072] As used herein, the term "acute pain" refers to pain that develops suddenly, is a response to stimulation associated with, for example, surgery, trauma, and / or acute illness, and lasts or is expected to last for a short period of time (e.g., weeks, days, hours). The term "acute pain" includes, but is not limited to, mild to moderate, moderate, moderate to moderately severe, or moderate to severe acute pain.
[0073] As used herein, the term "chronic pain" refers to pain associated with a chronic disease such as UCPPS.
[0074] As used herein, the term "visceral pain" refers to any pain perceived by an individual secondary to a disease, disorder or condition of an internal organ.
[0075] As used herein, the term "allodynia" refers to pain due to a stimulus that is not normally painful.
[0076] As used herein, the term "causalgia" refers to a syndrome of persistent burning pain, allodynia, and hyperalgesia following traumatic neuropathy, often accompanied by vasomotor and sudomotor dysfunction and subsequent trophic changes.
[0077] As used herein, the term "hyperalgesia" refers to an increased response to a stimulus that would normally cause pain.
[0078] As used herein, the term "hyperalgesia" refers to a pain syndrome characterized by abnormal painful responses to stimuli, especially repetitive stimuli, and an elevated pain threshold.
[0079] As used herein, the term "increasing bladder contraction and relaxation" refers to any detectable increase in bladder contractile function following administration or use of a compound compared to an otherwise identical situation except that the compound has not been administered or used.
[0080] As used herein, the term "treating acute pain" refers to any detectable reduction in acute pain, such as any detectable reduction in the sensation or duration of acute pain, following administration or use of a compound, compared to an otherwise identical situation except that the compound has not been administered or used.
[0081] As used herein with respect to a chronic pain condition, the term "exacerbation" or "flare-up" refers to an increase in the intensity of the pain.
[0082] When used for example in the methods of treatment, uses, compositions and kits of the present application, an individual (e.g., an individual "in need thereof") is an individual who has been diagnosed with, suspected of having, and / or previously been treated for a disease, such as urinary chronic pelvic pain syndrome or pain associated with urinary chronic pelvic pain syndrome or bladder inflammation.
[0083] II. Methods and uses of the present application
[0084] Applicants have shown that the compound of formula I, which is an NSAID derivative covalently linked to a H2S-releasing moiety, wherein the NSAID is ketoprofen and the H2S-releasing moiety is 4-hydroxythiobenzamide (TBZ), sometimes referred to as ATB-352, can relieve bladder inflammation and pain associated with urinary chronic pelvic pain syndrome. For example, applicants have studied the acute effects of the compound of formula I on inflammation, visceral bladder pain, and bladder function, and have shown that the compound of formula I can relieve visceral bladder and / or pelvic pain and bladder inflammation in an established mouse model of interstitial cystitis / bladder pain syndrome (IC / BPS). The compound of formula I has also been shown to improve bladder contractile function in the IC / BPS model. Surprisingly, the compound of formula I was found to be superior to the parent ketoprofen compound in relieving visceral bladder and / or pelvic pain and bladder inflammation and improving bladder contractile function in the IC / BPS model.
[0085] Thus, the present application includes a method of treating pain associated with urinary chronic pelvic pain syndrome (UCPPS) in an individual in need thereof, comprising administering to the individual an effective amount of a compound of formula I,
[0086]
[0087] or a pharmaceutically acceptable salt, prodrug and / or solvate thereof.
[0088] The present application also includes the use of a compound of Formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof in treating pain associated with UCPPS in an individual; the use of a compound of Formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof in the preparation of a medicament for treating pain associated with UCPPS in an individual; and a compound of Formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof for treating pain associated with UCPPS in an individual.
[0089] Those skilled in the art will appreciate that a syndrome is characterized by or indicative of one or more diseases, disorders or conditions. Thus, those skilled in the art will appreciate that UCPPS is a syndrome that includes interstitial cystitis / bladder pain syndrome (IC / BPS) and chronic prostatitis / chronic pelvic pain syndrome (CP / CPPS).
[0090] Thus, the present application includes a method of treating pain associated with interstitial cystitis / bladder pain syndrome (IC / BPS) in an individual in need thereof, comprising administering to the individual an effective amount of a compound of formula I,
[0091]
[0092] or a pharmaceutically acceptable salt, prodrug and / or solvate thereof.
[0093] The present application also includes the use of a compound of Formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof in treating pain associated with IC / BPS in an individual; the use of a compound of Formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof in the preparation of a medicament for treating pain associated with IC / BPS in an individual; and a compound of Formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof for treating pain associated with IC / BPS in an individual.
[0094] In certain embodiments, the pain is associated with interstitial cystitis. Thus, in certain embodiments, a compound of Formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof is used or administered to treat pain associated with interstitial cystitis.
[0095] In certain embodiments, the pain is associated with bladder pain syndrome. Thus, in certain embodiments, the compound of Formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof is used or administered to treat pain associated with bladder pain syndrome.
[0096] The present application includes a method of treating pain associated with chronic prostatitis / chronic pelvic pain syndrome (CP / CPPS) in an individual in need thereof, comprising administering to the individual an effective amount of a compound of formula I,
[0097]
[0098] or a pharmaceutically acceptable salt, prodrug and / or solvate thereof.
[0099] The present application also includes the use of a compound of formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof in treating pain associated with CP / CPPS in an individual; the use of a compound of formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof in the preparation of a medicament for treating pain associated with CP / CPPS in an individual; and a compound of formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof for treating pain associated with CP / CPPS in an individual.
[0100] In certain embodiments, the pain associated with urinary chronic pelvic pain syndrome (UCPPS) is selected from one or more of visceral pain, neuropathic pain, neuralgia, allodynia, causalgia, hyperalgesia, hyperesthesia, hyperalgesia, and neuropathy secondary to surgery. In certain embodiments, UCPPS comprises IC / BPS and / or CP / CPPS. Thus, in certain embodiments, the pain associated with IC / BPS is selected from one or more of visceral pain, neuropathic pain, neuralgia, allodynia, causalgia, hyperalgesia, hyperesthesia, hyperalgesia, and neuropathy secondary to surgery. In certain embodiments, the pain associated with CP / CPPS is selected from one or more of visceral pain, neuropathic pain, neuralgia, allodynia, causalgia, hyperalgesia, hyperesthesia, hyperalgesia, and neuropathy secondary to surgery.
[0101] In certain embodiments, the pain associated with UCPPS is allodynia associated with UCPPS. In certain embodiments, the pain associated with IC / BPS is allodynia associated with IC / BPS. In certain embodiments, the pain associated with interstitial cystitis is allodynia associated with interstitial cystitis. In certain embodiments, the pain associated with bladder pain syndrome is allodynia associated with bladder pain syndrome. In certain embodiments, the pain associated with CP / CPPS is allodynia associated with CP / CPPS. In certain embodiments, allodynia associated with UCPPS is abdominal or pelvic allodynia associated with UCPPS. In certain embodiments, allodynia associated with IC / BPS is abdominal or pelvic allodynia associated with IC / BPS. In certain embodiments, allodynia is abdominal or pelvic allodynia associated with IC / BPS. In certain embodiments, allodynia associated with CP / CPPS is abdominal or pelvic allodynia associated with CP / CPPS.
[0102] In certain embodiments, pain associated with UCPPS is hyperalgesia associated with UCPPS. In certain embodiments, pain associated with IC / BPS is hyperalgesia associated with IC / BPS. In certain embodiments, pain associated with interstitial cystitis is hyperalgesia associated with interstitial cystitis. In certain embodiments, pain associated with hyperalgesia associated with CP / CPPS is hyperalgesia associated with bladder pain syndrome. In certain embodiments, pain associated with CP / CPPS is hyperalgesia associated with CP / CPPS.
[0103] In certain embodiments, the pain associated with UCPPS is selected from one or more of lower abdominal (pelvic) pain, bladder pain, suprapubic pain, vaginal pain, pain in the penis, testicles, scrotum or perineum, urethral pain, dyspareunia or pain, pressure or discomfort that may increase with bladder filling. In certain embodiments, UCPPS comprises IC / BPS and / or CP / CPPS.
[0104] In certain embodiments, the pain associated with UCPPS is visceral pain associated with UCPPS. In certain embodiments, the pain associated with interstitial cystitis / bladder pain syndrome (IC / BPS) is visceral pain associated with interstitial cystitis / bladder pain syndrome (IC / BPS). In certain embodiments, the pain associated with interstitial cystitis is visceral pain associated with interstitial cystitis. In certain embodiments, the pain associated with bladder pain syndrome is visceral pain associated with bladder pain syndrome. In certain embodiments, the pain associated with CP / CPPS is visceral pain associated with CP / CPPS. In certain embodiments, the visceral pain is visceral abdominal pain.
[0105] In certain embodiments, the pain associated with urinary chronic pelvic pain syndrome (UCPPS) is acute and / or chronic pain associated with urinary chronic pelvic pain syndrome (UCPPS). In certain embodiments, the pain associated with interstitial cystitis / bladder pain syndrome (IC / BPS) is acute and / or chronic pain associated with interstitial cystitis / bladder pain syndrome (IC / BPS). In certain embodiments, the pain associated with interstitial cystitis is acute and / or chronic pain associated with interstitial cystitis. In certain embodiments, the pain associated with bladder pain syndrome is acute and / or chronic pain associated with bladder pain syndrome. In certain embodiments, the pain associated with CP / CPPS is acute and / or chronic pain associated with CP / CPPS.
[0106] In certain embodiments, the pain associated with urinary chronic pelvic pain syndrome (UCPPS) is chronic pain associated with urinary chronic pelvic pain syndrome (UCPPS). In certain embodiments, the pain associated with interstitial cystitis / bladder pain syndrome (IC / BPS) is chronic pain associated with interstitial cystitis / bladder pain syndrome (IC / BPS). In certain embodiments, the pain associated with interstitial cystitis is chronic pain associated with interstitial cystitis. In certain embodiments, the pain associated with bladder pain syndrome is chronic pain associated with bladder pain syndrome. In certain embodiments, the pain associated with CP / CPPS is chronic pain associated with CP / CPPS.
[0107] In certain embodiments, the pain associated with urinary chronic pelvic pain syndrome (UCPPS) is acute pain associated with urinary chronic pelvic pain syndrome (UCPPS). In certain embodiments, the pain associated with interstitial cystitis / bladder pain syndrome (IC / BPS) is acute pain associated with interstitial cystitis / bladder pain syndrome (IC / BPS). In certain embodiments, the pain associated with interstitial cystitis is acute pain associated with interstitial cystitis. In certain embodiments, the pain associated with bladder pain syndrome is acute pain associated with bladder pain syndrome. In certain embodiments, the pain associated with CP / CPPS is acute pain associated with CP / CPPS.
[0108] In certain embodiments, the acute pain associated with UCPPS is a temporary increase or sudden onset of pain associated with UCPPS. In certain embodiments, the acute pain associated with interstitial cystitis / bladder pain syndrome (IC / BPS) is a temporary increase or sudden onset of pain associated with interstitial cystitis / bladder pain syndrome (IC / BPS). In certain embodiments, the acute pain associated with interstitial cystitis is a temporary increase or sudden onset of pain associated with interstitial cystitis. In certain embodiments, the acute pain associated with bladder pain syndrome is a temporary increase or sudden onset of pain associated with bladder pain syndrome. In certain embodiments, the acute pain associated with CP / CPPS is a temporary increase or sudden onset of pain associated with CP / CPPS.
[0109] In certain embodiments, acute pain refers to pain that is expected to subside in a short time (e.g., 14 days or less). In certain embodiments, acute pain refers to pain that is expected to last for a longer time (e.g., 15 days or more). Acute pain is distinguishable from chronic pain.
[0110] In certain embodiments, acute pain lasts less than about 14 days, less than about 12 days, less than about 10 days, less than about 7 days, less than about 5 days, or less than 3 days from the onset of acute pain. In certain embodiments, acute pain lasts from about 1 day to about 14 days, from about 1 day to about 12 days, from about 1 day to about 10 days, from about 1 day to about 7 days, from about 1 day to about 5 days, from about 1 day to about 3 days, from about 3 days to 14 days, from about 3 days to about 10 days, from about 3 days to 7 days, or from about 5 days to about 10 days.
[0111] In certain embodiments, the acute pain occurs intermittently, lasting for more than 3 months, or more than 6 months.
[0112] The present application also includes a method of treating urinary chronic pelvic pain syndrome (UCPPS) in an individual in need thereof, comprising administering to the individual an effective amount of a compound of formula I,
[0113]
[0114] or a pharmaceutically acceptable salt, prodrug and / or solvate thereof.
[0115] The present application also includes the use of a compound of Formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof in treating UCPPS in an individual; the use of a compound of Formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof in the preparation of a medicament for treating UCPPS in an individual; and a compound of Formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof for treating UCPPS in an individual.
[0116] In certain embodiments, UCPPS comprises interstitial cystitis / bladder pain syndrome (IC / BPS) and chronic prostatitis / chronic pelvic pain syndrome (CP / CPPS).
[0117] Therefore, the present application also includes a method of treating interstitial cystitis / bladder pain syndrome (IC / BPS) in an individual in need thereof, comprising administering to the individual an effective amount of a compound of formula I,
[0118]
[0119] or a pharmaceutically acceptable salt, prodrug and / or solvate thereof.
[0120] The present application also includes the use of a compound of Formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof in treating IC / BPS in an individual; the use of a compound of Formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof in the preparation of a medicament for treating IC / BPS in an individual; and a compound of Formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof for treating IC / BPS in an individual.
[0121] In certain embodiments, the compound of formula I or its pharmaceutically acceptable salt, prodrug and / or solvate is used or administered to treat interstitial cystitis. In certain embodiments, the compound of formula I or its pharmaceutically acceptable salt, prodrug and / or solvate is used or administered to treat bladder pain syndrome.
[0122] The present application also includes a method of treating chronic prostatitis / chronic pelvic pain syndrome (CP / CPPS) in an individual in need thereof, comprising administering to the individual an effective amount of a compound of formula I,
[0123]
[0124] or a pharmaceutically acceptable salt, prodrug and / or solvate thereof.
[0125] The present application also includes the use of a compound of formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof in treating CP / CPPS in an individual; the use of a compound of formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof in the preparation of a medicament for treating CP / CPPS in an individual; and a compound of formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof for treating CP / CPPS in an individual.
[0126] The present application also includes a method of treating one or more symptoms associated with urinary chronic pelvic pain syndrome (UCPPS) in an individual in need thereof, comprising administering to the individual an effective amount of a compound of formula I,
[0127]
[0128] or a pharmaceutically acceptable salt, prodrug and / or solvate thereof.
[0129] The present application also includes the use of a compound of Formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof in treating one or more symptoms associated with UCPPS in an individual; the use of a compound of Formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof in the preparation of a medicament for treating one or more symptoms associated with UCPPS in an individual; and a compound of Formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof for treating one or more symptoms associated with UCPPS in an individual.
[0130] In certain embodiments, UCPPS comprises IC / BPS and / or CP / CPPS. Therefore, in certain embodiments, the present application also includes a method or use of a compound of formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof for treating one or more symptoms associated with IC / BPS. In certain embodiments, the present application also includes a method or use of a compound of formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof for treating one or more symptoms associated with CP / CPPS.
[0131] In certain embodiments, the one or more symptoms are selected from irritative urinary symptoms, urinary frequency, urinary urgency, nocturia, urinary incontinence, and suprapubic or pelvic pain associated with and relieved by urination.
[0132] The applicant has demonstrated that the compound of formula I can be used to relieve bladder inflammation. Therefore, the present application also includes a method of treating bladder inflammation in an individual in need thereof, comprising administering to the individual an effective amount of the compound of formula I,
[0133]
[0134] or a pharmaceutically acceptable salt, prodrug and / or solvate thereof.
[0135] The present application also includes the use of a compound of formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof in treating bladder inflammation in an individual; the use of a compound of formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof in the preparation of a medicament for treating bladder inflammation in an individual; and a compound of formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof for treating bladder inflammation in an individual.
[0136] In certain embodiments, bladder inflammation is associated with urinary chronic pelvic pain syndrome (UCPPS). In certain embodiments, bladder inflammation is associated with interstitial cystitis / bladder pain syndrome (IC / BPS). In certain embodiments, bladder inflammation is associated with interstitial cystitis. In certain embodiments, bladder inflammation is associated with bladder pain syndrome. In certain embodiments, bladder inflammation is associated with chronic prostatitis / chronic pelvic pain syndrome (CP / CPPS).
[0137] The present application includes a method of increasing bladder contraction and relaxation in an individual in need thereof, comprising administering to the individual an effective amount of a compound of formula I,
[0138]
[0139] or a pharmaceutically acceptable salt, prodrug and / or solvate thereof.
[0140] The present application also includes the use of a compound of formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof in increasing bladder contraction and relaxation in an individual; the use of a compound of formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof in the preparation of a medicament for increasing bladder contraction and relaxation in an individual; and a compound of formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof for increasing bladder contraction and relaxation in an individual.
[0141] In certain embodiments, the individual is an individual suffering from UCPPS. In certain embodiments, UCPPS is IC / BPS and / or CP / CPPS.
[0142] The present application includes a method of treating acute pain in an individual in need thereof, comprising administering to the individual an effective amount of a compound of formula I,
[0143]
[0144] or a pharmaceutically acceptable salt, prodrug and / or solvate thereof.
[0145] The present application also includes the use of a compound of formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof in treating acute pain in an individual; the use of a compound of formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof in the preparation of a medicament for treating acute pain in an individual; and a compound of formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof for treating acute pain in an individual.
[0146] In certain embodiments, the acute pain is a temporary exacerbation or flare-up.
[0147] In certain embodiments, the acute pain refers to the pain that is expected to disappear in a short time (for example, 14 days or less). In certain embodiments, acute pain is less than about 14 days, less than about 12 days, less than about 10 days, less than about 7 days, less than about 5 days or less than 3 days from the onset of acute pain. In certain embodiments, acute pain lasts from about 1 day to about 14 days, about 1 day to about 12 days, about 1 day to about 10 days, about 1 day to about 7 days, about 1 day to about 5 days, about 1 day to about 3 days, about 3 days to 14 days, about 3 days to about 10 days, about 3 days to 7 days or about 5 days to about 10 days.
[0148] In certain embodiments, the acute pain occurs intermittently, lasting for more than 3 months, or more than 6 months.
[0149] In certain embodiments, the acute pain is postoperative pain caused by abdominal and / or pelvic surgery. The present application also includes a method for treating acute pain caused by abdominal and / or pelvic surgery in an individual in need thereof, comprising administering to the individual an effective amount of a compound of formula I,
[0150]
[0151] or a pharmaceutically acceptable salt, prodrug and / or solvate thereof.
[0152] The present application also includes the use of a compound of formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof in treating acute pain caused by abdominal and / or pelvic surgery in an individual; the use of a compound of formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof in the preparation of a medicament for treating acute pain caused by abdominal and / or pelvic surgery in an individual; and a compound of formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof for treating acute pain caused by abdominal and / or pelvic surgery in an individual.
[0153] In certain embodiments, the abdominal and / or pelvic surgery is selected from, but is not limited to, inguinal hernia repair, such as open inguinal hernia repair, abdominal hysterectomy, abdominal laparotomy, cholecystectomy, vaginal hysterectomy, ventral hernia repair, myomectomy, salpingo-oophorectomy, bariatric surgery, partial colectomy, and gynecological or genitourinary surgery.
[0154] In certain embodiments, the abdominal and / or pelvic surgery is selected from but not limited to inguinal hernia repair, such as open inguinal hernia repair, abdominal hysterectomy, abdominal laparotomy, or bariatric surgery. In certain embodiments, the abdominal and / or pelvic surgery is inguinal hernia repair. In certain embodiments, inguinal hernia repair is open inguinal hernia repair.
[0155] In certain embodiments, the abdominal and / or pelvic surgery is abdominal laparotomy or bariatric surgery. In certain embodiments, the abdominal and / or pelvic surgery is bariatric surgery.
[0156] In certain embodiments, the acute pain is not postoperative pain.
[0157] In certain embodiments, the individual in need is an individual suffering from urinary chronic pelvic pain syndrome (UCPPS), pain associated with UCPPS, and / or bladder inflammation. In certain embodiments, the individual in need is an individual suffering from interstitial cystitis / bladder pain syndrome (IC / BPS), pain associated with IC / BPS, and / or bladder inflammation. In certain embodiments, the individual in need is an individual suffering from interstitial cystitis, pain associated with interstitial cystitis, and / or bladder inflammation. In certain embodiments, the individual in need is an individual suffering from bladder pain syndrome, pain associated with bladder pain syndrome, and / or bladder inflammation. In certain embodiments, the individual in need is an individual suffering from chronic prostatitis / chronic pelvic pain syndrome (CP / CPPS), pain associated with CP / CPPS, and / or bladder inflammation.
[0158] In certain embodiments, the compound of formula I is in the form of a pharmaceutically acceptable solvate. In certain embodiments, the compound of formula I is in neutral form (i.e., not a salt). In certain embodiments, the compound of formula I is a prodrug of the compound of formula I. In certain embodiments, the compound of formula I is a solvate of a prodrug of the compound of formula I.
[0159] The present application also includes the use of a combination of a compound of formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof with another known agent for treating chronic pelvic pain syndrome (UCPPS) of the urinary system, pain associated with UCPPS, bladder inflammation and / or acute pain in the treatment of chronic pelvic pain syndrome (UCPPS) of the urinary system, pain associated with UCPPS, bladder inflammation and / or acute pain in an individual in need. The present application also includes the use of a combination of a compound of formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof with another known agent for treating chronic pelvic pain syndrome (UCPPS) of the urinary system, pain associated with UCPPS, bladder inflammation and / or acute pain in the preparation of a medicament for treating chronic pelvic pain syndrome (UCPPS) of the urinary system, pain associated with UCPPS, bladder inflammation and / or acute pain in an individual in need. The present application also includes a compound of formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof, which is used in combination with another known agent for treating chronic pelvic pain syndrome (UCPPS) of the urinary system, pain associated with UCPPS, bladder inflammation and / or acute pain, for treating chronic pelvic pain syndrome (UCPPS) of the urinary system, pain associated with UCPPS, bladder inflammation and / or acute pain in individuals in need. In certain embodiments, the method or use is used to treat pain associated with UCPPS. In certain embodiments, the method or use is used to treat pain associated with IC / BPS. In certain embodiments, the method or use is used to treat pain associated with interstitial cystitis. In certain embodiments, the method or use is used to treat pain associated with bladder pain syndrome. In certain embodiments, the method or use is used to treat pain associated with CP / CPPS. In certain embodiments, the pain is acute pain. In certain embodiments, the method or use is used to treat IC / BPS. In certain embodiments, the method or use is used to treat interstitial cystitis. In certain embodiments, the method or use is used to treat bladder pain syndrome. In certain embodiments, the method or use is for treating CP / CPPS.
[0160] In certain embodiments, when used with other known agents useful for treating or preventing pain associated with UCPPS, UCPPS, or bladder inflammation, the methods and uses of the present application reduce the amount of the other known agents used or administered. In certain embodiments, when used with other known agents useful for treating or preventing pain associated with UCPPS, UCPPS, or bladder inflammation, the methods and uses of the present application reduce the amount of the other known agents by about 40% to 60% within about 12 hours, about 24 hours, about 36 hours, about 48 hours, about 60 hours, or about 72 hours after administration.
[0161] In certain embodiments, another known agent for treating UCPPS or pain associated with UCPPS is selected from antihistamines, including H1 blockers, such as hydroxyzine hydrochloride, and H2 blockers, such as cimetidine, dimethyl sulfoxide; pain modulators, including tricyclic antidepressants, such as amitriptyline, anticonvulsants, such as gabapentin and dimethyl sulfoxide, narcotic antagonists, corticosteroids, antirheumatic drugs, immunomodulators, immunosuppressants, such as prednisone and triamcinolone, interleukin production inhibitors, bladder mucosal protectants, such as pentosan polysulfate and hyaluronic acid, chondroitin sulfate, leukotriene-D4 receptor antagonist montelukast, L-arginine, oxybutynin, tolterodine, hormone modulators, such as leuprolide acetate, anti-inflammatory drugs, such as anti-tumor necrosis factor (anti-TNF), anesthetics and analgesics, such as opioids and tramadol.
[0162] In one embodiment, the corticosteroid is selected from the group consisting of cortisone, hydrocortisone, prednisone, methylprednisolone, deflazacort, prednisolone, triamcinolone, dexamethasone, betamethasone, halopednisone, beclomethasone, and fludrocortisone, and combinations thereof.
[0163] In certain embodiments, the compound of Formula I or a pharmaceutically acceptable salt and / or solvate thereof is used or administered alone, without other agents known to be useful for treating or preventing pain associated with urological chronic pelvic pain syndrome (UCPPS).
[0164] Those skilled in the art will appreciate that pain rating scales are well known and used to measure pain intensity in daily clinical practice. For example, commonly used measurement scales include visual analog scales (VAS), graphic scale rating methods (GRS), simple description scales (SDS), numeric rating scales (NRS), facial expression rating methods (FRS) and total pain relief (TOTPAR) and / or the sum of pain intensity differences (SPID). In particular, in acute pain, total pain relief (TOTPAR) and / or the sum of pain intensity differences (SPID) are commonly used indicators for assessing pain in the art. Numeric rating scales (NRS) similar to VAS are also available in acute pain. In certain embodiments, the visual analog scale (VAS) is a 10 cm vertical or horizontal line with word anchors at both ends, such as "painless" at one end and "extremely severe pain" at the other end. Patients are asked to mark along the line to indicate pain intensity. In the visual analog scale (VAS), moderate or severe pain is defined as pain intensity of > about 50mm on the 0mm-100mm visual analog scale (VAS). In certain embodiments, moderate pain is characterized by pain intensity of > about 50mm and < about 70mm on the 0mm-100mm VAS. And severe pain is characterized by pain intensity of > about 70mm on the 0mm-100mm VAS. The graph scale evaluation method (GRS) is a variant of the visual scale, which adds words such as "painless", "mild", "severe" or numbers between the two ends. The simple description scale (SDS) is a list of adjectives describing different degrees of pain intensity, such as "painless", "mild", "moderate" or "severe". The digital pain rating scale (NPRS) refers to a numerical rating of 0 to 10 or 0 to 5, or a visual scale comprising text and numbers. The visual analog scale (VAS) version of WOMAC is also commonly used.
[0165] In certain embodiments, one or more biomarkers known to represent pathways that lead to pain relief are activated are used to assess treatment of an individual, including, but not limited to, plasma levels of thromboxane B2 (TXB2), prostaglandin E2 (PGE2), interleukin 1β (IL-1β), interleukin 6 (IL-6), tumor necrosis factor α (TNF-α), and / or C-reactive protein (CRP). The levels of these markers indicative of pain response are known in the art, and methods for detecting the levels of these markers in an individual are also known.
[0166] In certain embodiments, the pain is mild to moderate, moderate to moderately severe, or moderately severe to severe.
[0167] In certain embodiments, the methods and uses of the present application provide pain relief within about 30 minutes to about 4 hours, about 1 hour to about 4 hours, about 1 hour to about 3 hours, about 1 hour to about 3 hours, about 1 hour to about 2 hours, about 2 hours to about 3 hours after administration of the compound of formula I. In certain embodiments, the methods of the present application provide pain relief within about 1 hour to about 3 hours, about 1 hour to about 2 hours, about 2 hours to about 3 hours after administration of the compound of formula I
[0168] The effective amount may vary depending on factors such as the disease state, age, sex and / or weight of the individual. The amount of a given compound corresponding to the stated amount will vary depending on various factors, such as a given drug or compound, pharmaceutical formulation, route of administration, type of viral infection in the individual being treated, etc., but can still be routinely determined by one skilled in the art. An effective amount is an amount that manifests as an improvement or alleviation of any disease symptom following treatment therewith.
[0169] The dosage of the compound of formula I or its pharmaceutically acceptable salt, prodrug and / or solvate may vary due to a variety of factors, such as the pharmacodynamic properties of the compound, the mode of administration, the age, health and weight of the recipient, the nature and extent of the symptoms, the frequency of treatment and the type of concomitant treatment (if any), and the clearance rate of the compound in the subject to be treated. Those skilled in the art can determine the appropriate dosage based on the above factors. The compound of formula I or its pharmaceutically acceptable salt, prodrug and / or solvate can be administered first at a suitable dosage, which can be adjusted as needed, depending on the clinical response. The dosage is usually selected to maintain the serum level of the compound at about 0.01 μg / cc to about 1000 μg / cc, or about 0.1 μg / cc to about 100 μg / cc. As a representative example, the oral dosage of the compound of formula I or its pharmaceutically acceptable salt, prodrug and / or solvate is between about 1 mg per day and about 1000 mg per day for adults, preferably about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, about 500 mg per day. For parenteral administration or use, the representative amount of administration or use is about 0.001 mg / kg to about 10 mg / kg, about 0.01 mg / kg to about 10 mg / kg, about 0.01 mg / kg to about 1 mg / kg or about 0.1 mg / kg to about 1 mg / kg. For oral administration or use, its representative amount is about 0.001 mg / kg to about 10 mg / kg or about 0.1 mg / kg to about 10 mg / kg. For suppository administration or use, its representative amount is about 0.1 mg / kg to about 10 mg / kg.
[0170] In certain embodiments, the oral dosage of a compound of Formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof ranges from about 50 mg per day to about 500 mg per day for an adult, preferably about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 250 mg, about 275 mg, about 300 mg, about 325 mg, about 350 mg, about 375 mg, about 400 mg, about 425 mg, about 450 mg, about 475 mg, about 500 mg per day. In certain embodiments, the oral dosage of a compound of Formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof ranges from about 50 mg per day to about 500 mg per day, about 100 mg per day to about 400 mg per day, about 200 mg per day to about 400 mg per day, about 250 mg per day to about 350 mg per day, or about 250 mg per day to about 325 mg per day. In certain embodiments, the oral dosage of the compound of formula I or its pharmaceutically acceptable salt, prodrug and / or solvate ranges from about 200 mg per day to about 400 mg per day or from about 250 mg per day to about 325 mg per day. In certain embodiments, the oral dosage of the compound of formula I or its pharmaceutically acceptable salt, prodrug and / or solvate is about 325 mg per day.
[0171] In certain embodiments, the compound of Formula I is formulated for oral administration or use, and the compound of Formula I is suitably in the form of a tablet or other solid form oral dosage form, wherein each tablet contains 0.25, 0.5, 0.75, 1, 5, 10, 20, 25, 30, 40, 50, 60, 70, 75, 80, 90, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 400, 450 or 500 mg of active ingredient.
[0172] In certain embodiments, the compound of formula I or its pharmaceutically acceptable salt, prodrug and / or solvate can be administered or used in a single daily dose, or the total daily dose can be divided into two, three, four, five or six daily doses. In certain embodiments, the compound of formula I or its pharmaceutically acceptable salt, prodrug and / or solvate is administered 2, 3, 4, 5 or 6 times a day.
[0173] In certain embodiments, for example, when a compound of Formula I is used or administered to treat acute pain (including acute pain associated with UCPPS), the compound of Formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof is administered for 1 to 14 days, 2 to 10 days, 2 to 9 days, 2 to 8 days, 2 to 7 days, 2 to 6 days, or 3 to 5 days. In certain embodiments, the acute pain is a temporary increase or sudden onset. In certain embodiments, the compound of Formula I is used or administered intermittently as described for more than 3 months or more than 6 months.
[0174] In certain embodiments, the oral dose of the compound of Formula I, or a pharmaceutically acceptable salt, prodrug and / or solvate thereof, is about 400 mg to about 500 mg per day, and the compound of Formula I, or a pharmaceutically acceptable salt, prodrug and / or solvate thereof, is administered for 1 day. In certain embodiments, the oral dose of the compound of Formula I, or a pharmaceutically acceptable salt, prodrug and / or solvate thereof, is about 400 mg to about 500 mg per day, about 400 mg to about 450 mg per day, about 450 mg to about 500 mg per day, or about 400 mg per day, about 450 mg per day, or about 500 mg per day, and the compound of Formula I, or a pharmaceutically acceptable salt, prodrug and / or solvate thereof, is administered for 1 day.
[0175] In certain embodiments, the oral dose of the compound of Formula I, or a pharmaceutically acceptable salt, prodrug and / or solvate thereof, is from about 200 mg per day to about 400 mg per day, from about 250 mg per day to about 350 mg per day, or from about 250 mg per day to about 325 mg per day, and the compound of Formula I, or a pharmaceutically acceptable salt, prodrug and / or solvate thereof, is administered for 1 day to 10 days, 1 day to 8 days, 1 day to 7 days, 1 day to 5 days, 2 days to 7 days, 3 days to 7 days, 4 days to 7 days, 5 days to 7 days, 6 days to 7 days, 2 days to 5 days, 3 days to 5 days, 4 days to 5 days, 2 days, 3 days, 4 days, 5 days, 6 days or 7 days. In certain embodiments, the oral dose of the compound of Formula I, or a pharmaceutically acceptable salt, prodrug and / or solvate thereof, is from about 250 mg per day to about 350 mg per day, or from about 250 mg per day to about 325 mg per day, or about 250 mg per day, about 275 mg per day, about 300 mg per day, or about 350 mg per day, and the compound of Formula I, or a pharmaceutically acceptable salt, prodrug and / or solvate thereof, is administered for 1 day to 8 days, 1 day to 7 days, 1 day to 5 days, 2 days to 7 days, 3 days to 7 days, 4 days to 7 days, 5 days to 7 days, 6 days to 7 days, 2 days to 5 days, 3 days to 5 days, 4 days to 5 days, 2 days, 3 days, 4 days, 5 days, 6 days or 7 days.
[0176] The length of the treatment period depends on a variety of factors, such as the severity of acute pain, the age of the individual, the concentration and / or activity and / or combination thereof of the compound of formula I or its pharmaceutically acceptable salt, prodrug and / or solvate. It should also be understood that in the course of a particular treatment regimen, the effective dose of the compound used for treatment may increase or decrease. The change in dosage may be determined and become apparent by standard diagnostic assays known in the art. For example, the compound of formula I or its pharmaceutically acceptable salt, prodrug and / or solvate is administered to the individual in an amount and duration sufficient to treat the individual.
[0177] In one embodiment, the subject is a mammal. In another embodiment, the subject is a human. In one embodiment, the subject is a non-human animal.
[0178] The compound of formula I or its pharmaceutically acceptable salt, prodrug and / or solvate can be used or applied alone, or used or applied in combination with other known drugs for treating pain associated with urinary chronic pelvic pain syndrome (UCPPS), UCPPS, acute pain and / or bladder inflammation. When used or applied in combination with other drugs or therapies, one embodiment is to use or apply the compound of formula I or its pharmaceutically acceptable salt, prodrug and / or solvate simultaneously with these drugs or therapies. As used herein, "simultaneous administration" or "simultaneous use" of two substances or therapies to an individual refers to providing each of two substances or therapies so that they are biologically active in the individual body at the same time. The specific details of administration or use depend on the pharmacokinetics of the two substances or therapies when they are present in each other, and if the pharmacokinetics are appropriate, it can include administering or using two substances or therapies within a few hours of each other, or even administering or using another substance or therapy within 24 hours after administering or using one substance or therapy. Designing a suitable dosage regimen is routine for those skilled in the art. In a specific embodiment, the substances or therapies are administered or used substantially simultaneously, i.e., administered or used within a few minutes of each other, or, in the case of administering or using two or more substances, administered or used in the form of a single composition. Another embodiment of the present application is to administer or use a combination of preparations or therapies to an individual in a non-simultaneous manner.
[0179] In certain embodiments, the compound of Formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof, or the composition of the present application is used or administered in combination with other known drugs, which can be used to treat or prevent pain associated with urinary chronic pelvic pain syndrome (UCPPS), UCPPS, acute pain and / or bladder inflammation.
[0180] In one embodiment of the methods and uses of the present application, the compound of formula I or its pharmaceutically acceptable salt, prodrug and / or solvate is administered orally or used. In one embodiment, the compound of formula I or its pharmaceutically acceptable salt, prodrug and / or solvate is administered or used by parenteral administration. In one embodiment, the compound of formula I or its pharmaceutically acceptable salt, prodrug and / or solvate is administered or used intramuscularly, transepithelially, topically (including transdermal administration).
[0181] In one embodiment, the pharmaceutically acceptable salt is an acid addition salt or a base addition salt. The selection of a suitable salt can be performed by a person skilled in the art (see, for example, SM Berge, et al., "Pharmaceutical Salts," J. Pharm. Sci. 1977, 66, 1-19)
[0182] Acid addition salts suitable for individual treatment or compatible with individual treatment are any nontoxic organic or inorganic acid addition salts of any basic compound. For example, the basic compound forming the acid addition salt includes a compound containing an amine group. Exemplary inorganic acids forming suitable salts include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid and phosphoric acid, and acidic metal salts, such as sodium monohydrogen orthophosphate and potassium hydrogen sulfate. Exemplary organic acids forming suitable salts include monocarboxylic acids, dicarboxylic acids and tricarboxylic acids. For example, these exemplary organic acids are acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, malic acid, tartaric acid, citric acid, ascorbic acid, maleic acid, hydroxymaleic acid, benzoic acid, hydroxybenzoic acid, phenylacetic acid, cinnamic acid, mandelic acid, salicylic acid, 2-phenoxybenzoic acid, p-toluenesulfonic acid and other sulfonic acids, such as methanesulfonic acid, ethanesulfonic acid and 2-hydroxyethanesulfonic acid. In one embodiment, monoacid salts or diacid salts are formed, which exist in hydrated, solvated or substantially anhydrous forms. In general, acid addition salts are more soluble in water and various hydrophilic organic solvents, and generally have higher melting points than their free base forms. The selection criteria for suitable salts are well known to those skilled in the art. Other non-pharmaceutically acceptable salts may be used, such as, but not limited to, oxalates, for example, for separation of the compounds of the present application for laboratory use, or for subsequent conversion into pharmaceutically acceptable acid addition salts.
[0183] Base addition salts suitable for individual treatment or compatible with individual treatment are any nontoxic organic base or inorganic base addition salts of any acidic compound. For example, the acidic compound forming the base addition salt includes a compound containing a carboxylic acid group. The exemplary inorganic bases forming suitable salts include lithium hydroxide, sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide or barium hydroxide and ammonia. The exemplary organic bases forming suitable salts include aliphatic organic amines, alicyclic organic amines or aromatic organic amines, such as isopropylamine, methylamine, trimethylamine, picoline, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucosamine, theobromine, purine, piperazine, piperidine, N-ethylpiperidine, polyamine resins, etc. Exemplary organic bases include isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline and caffeine. It may be useful to select an appropriate salt, for example, so that the ester functional groups (if any) at other positions in the compound will not be hydrolyzed. The selection criteria for appropriate salts are well known to those skilled in the art.
[0184] Solvates of the compounds of formula I include, for example, those made with pharmaceutically acceptable solvents. Examples of these solvents include water (the resulting solvates are called hydrates) and ethanol, etc. Suitable solvents are physiologically tolerable at the administered dose.
[0185] The compound of formula I or its pharmaceutically acceptable salt, prodrug and / or solvate may further exist in an amorphous form or different polymorphic forms, and any amorphous form, any polymorphic form or mixture thereof formed is considered to be included in the scope of the present application.
[0186] The compound of formula I or its pharmaceutically acceptable salt, prodrug and / or solvate can be further radiolabeled, therefore, all radiolabeled forms of the compound of the present application are included within the scope of the present application. The compound of the present application also includes compounds containing one or more radioactive atoms in its structure.
[0187] III. Composition of the present application
[0188] In one embodiment, the compound of formula I or its pharmaceutically acceptable salt, prodrug and / or solvate is suitably formulated into a composition using one or more carriers in a conventional manner.
[0189]
[0190] The compound of formula I or its pharmaceutically acceptable salt and / or solvate is suitably formulated into a pharmaceutical composition for administration to an individual in a biocompatible form suitable for in vivo administration. Accordingly, the compound of formula I or its pharmaceutically acceptable salt and / or solvate is suitably formulated into a pharmaceutical composition, which comprises the compound of formula I or its pharmaceutically acceptable salt, prodrug and / or solvate and a pharmaceutically acceptable carrier, respectively.
[0191]
[0192] Therefore, the present application also includes a method or use for treating pain associated with the above-mentioned urinary chronic pelvic pain syndrome (UCPPS), UCPPS, acute pain and / or bladder inflammation by administering or using a composition comprising a compound of formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof.
[0193] Formula I compound or its pharmaceutically acceptable salt, prodrug and / or solvate can be used alone suitably, but usually is used together with acceptable carrier in the form of composition.According to the mode of administration, composition comprises one or more forms of about 0.05 % by weight to about 99 % by weight or about 0.10 % by weight to about 70 % by weight and about 1 % by weight to about 99.95 % by weight or about 30 % by weight to about 99.90 % by weight of acceptable carrier, and all percentages by weight are based on the total weight of the composition.
[0194] The compound of formula I or its pharmaceutically acceptable salt, prodrug and / or solvate can also be administered or used to an individual in a variety of forms according to the selected route of administration, as will be understood by those skilled in the art. In one embodiment, the compound of formula I or its pharmaceutically acceptable salt, prodrug and / or solvate is administered orally (including sublingual and buccal) or parenterally (including intravenous, intraperitoneal, subcutaneous, intramuscular, transepithelial, intranasal, intrapulmonary, intrathecal, rectal, topical, patch, pump or transdermal) and the compound, salt, prodrug and / or solvate are formulated accordingly, thereby administering or using to an individual I. Similarly, conventional methods and ingredients for selecting and preparing suitable compositions are described in, for example, Remington's Pharmaceutical Sciences (2000–20th Edition) and the United States Pharmacopeia: National Formulary (USP 24NF19) published in 1999.
[0195] Parenteral administration includes intravenous, intraarterial, intraperitoneal, subcutaneous, intramuscular, transepithelial, intranasal, intrapulmonary (e.g., by using an aerosol), intrathecal, rectal, local (including the use of a patch or other transdermal delivery device) mode of administration. Parenteral administration can be by continuous infusion within a selected time. The drug form suitable for injection includes sterile aqueous solutions or dispersions, and sterile powders for the temporary preparation of sterile injection solutions or dispersions. In all cases, the form is sterile and reaches a fluid that is easy to inject.
[0196] The compound of formula I or its pharmaceutically acceptable salt, prodrug and / or solvate can be administered orally, for example, with an inert diluent or an absorbable edible carrier, or encapsulated in a hard or soft gelatin capsule, or compressed into a tablet, or can be directly incorporated into the food of the diet. For oral therapeutic administration, the compound can be combined with an excipient and used in the form of a tablet, buccal tablet, tablet, capsule, sachet, pill, granule, lozenge, chewing gum, powder, syrup, elixir, wafer, aqueous solution and suspension, etc. In the case of tablets, the carrier used includes lactose, corn starch, sodium citrate and phosphate. Pharmaceutically acceptable excipients include binders (e.g., pregelatinized corn starch, polyvinylpyrrolidone, or hydroxypropylmethylcellulose); fillers (e.g., lactose, microcrystalline cellulose, or calcium phosphate); lubricants (e.g., magnesium stearate, talc, or silicon dioxide); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulfate). Tablets may be coated by methods well known in the art. For tablets, capsules, sachets, pills, or granules for oral administration, a pH-sensitive enteric coating, such as Eudragits designed to control the release of the active ingredient, may optionally be used. TM Oral dosage forms also include modified release formulations, such as immediate release formulations and timed release formulations. Examples of modified release formulations include, for example, sustained release formulations (SR), extended release formulations (ER, XR or XL), timed release formulations (time-release or timed-release), controlled release formulations (CR), or sustained sustained release formulations (CR or Contin), for example, in the form of coated tablets, osmotic delivery devices, coated capsules, microencapsulated microspheres, agglomerated particles (such as molecular sieve-type particles), fine hollow osmotic fiber bundles, short chopped hollow osmotic fibers, agglomerated or maintained in fiber wrapping. Timed release compositions can be formulated, such as liposomes or compositions in which the active compound is protected by a coating that is differentially degraded, such as by microencapsulation, multilayer coatings, etc. Liposomal delivery systems include, for example, small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholine. For oral administration in capsule form, useful carriers or diluents include lactose and dry corn starch.
[0197] Liquid preparations for oral administration may be in the form of, for example, solutions, syrups or suspensions, and may also be appropriately provided in the form of dry products for reconstitution with water or other suitable solvents before use. When aqueous suspensions and / or emulsions are taken orally, the compound of formula I or its pharmaceutically acceptable salts, prodrugs and / or solvates may be appropriately suspended or dissolved in an oil phase combined with an emulsifier and / or suspending agent. If desired, certain sweeteners and / or flavoring agents and / or coloring agents may also be added. Such liquid preparations for oral administration may be prepared by conventional methods with pharmaceutically acceptable additives, such as suspending agents (e.g., sorbitol syrup, methylcellulose or hydrogenated edible fats); emulsifiers (e.g., lecithin or gum arabic); non-aqueous carriers (almond oil, oily esters or ethanol); and preservatives (e.g., methylparaben or propylparaben or sorbic acid). Useful diluents include lactose and high molecular weight polyethylene glycols.
[0198] The compound of formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof can also be freeze-dried and the lyophilisate obtained used, for example, for the preparation of an injection product.
[0199] The compound of formula I or its pharmaceutically acceptable salt, prodrug and / or solvate can also be administered parenterally. The solution of the compound of formula I or its pharmaceutically acceptable salt, prodrug and / or solvate can be prepared in water with a surfactant such as hydroxypropylcellulose by appropriate mixing. Dispersions can also be prepared in glycerol, liquid polyethylene glycol, DMSO and mixtures thereof (with or without ethanol) and in oil. Under normal storage and use conditions, these preparations contain preservatives to prevent the growth of microorganisms. Those skilled in the art know how to prepare suitable preparations. For parenteral administration, a sterile solution of the compound of formula I or its pharmaceutically acceptable salt, prodrug and / or solvate is usually prepared, and the pH value of the solution is appropriately adjusted and buffered. For intravenous injection, the total concentration of the solute should be controlled to make the preparation isotonic. For ocular administration, ointments or drops can be delivered by an ocular administration system known in the art (e.g., an applicator or an eye dropper). Such compositions may include tear film mimics such as hyaluronic acid, chondroitin sulfate, hydroxypropylmethylcellulose or polyvinyl alcohol; preservatives such as sorbic acid, EDTA or benzylchromium chloride; and conventional amounts of diluents or carriers. For pulmonary administration, appropriate diluents or carriers will be selected to form an aerosol.
[0200] The compound of formula I or its pharmaceutically acceptable salt, prodrug and / or solvate can be formulated for parenteral administration by injection, including the use of conventional catheter insertion techniques or infusions. Injectable preparations can be provided in unit dosage forms, such as ampoules or multi-dose containers, and preservatives are added. The composition can be in the form of a sterile suspension, solution or emulsion in an oily or aqueous carrier, and may contain formulation excipients such as suspending agents, stabilizers and / or dispersants. In any case, the formulation form must be sterile and must be fluid to the extent that it is easy to inject. Alternatively, the compound of formula I or its pharmaceutically acceptable salt, prodrug and / or solvate is suitably in the form of a sterile powder for reconstitution with a suitable solvent (such as sterile pyrogen-free water) before use.
[0201] Compositions for nasal administration may conveniently be formulated as aerosols, drops, gels and powders.
[0202] For intranasal administration or inhalation administration, the compound of formula I or its pharmaceutically acceptable salt, prodrug and / or solvate can be conveniently delivered from a pump spray container (which is squeezed or pumped by the patient) or from a pressurized container or atomizer in the form of a solution, dry powder preparation or suspension. Aerosol preparations usually contain a solution or fine particle suspension of active substances in a physiologically acceptable aqueous or non-aqueous solvent, which is usually loaded into a sealed container in a single dose or multiple doses in a sterile form, and the sealed container can be a cartridge or a reloaded tube used in conjunction with an atomizing device. In addition, the sealed container can also be a single dispensing device, such as a single dose nasal inhaler or an aerosol sprayer equipped with a metering valve, for use and discarding. Wherein, the dosage form includes an aerosol sprayer, which includes a propellant, which can be a compressed gas (such as compressed air) or an organic propellant (such as fluorochlorocarbon). Suitable propellants include but are not limited to dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, heptafluoroalkane, carbon dioxide or other suitable gases. In the case of a pressurized aerosol, the dosage unit is appropriately determined by providing a valve to deliver a metered amount. The pressurized container or nebulizer may contain a solution or suspension of the active compound. Capsules and cartridges (e.g., made of gelatin) for use in an inhaler or insufflator may be configured to contain a powder mix of a compound of formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof and a suitable powder base such as lactose or starch. Aerosol formulations may also be in the form of a pump-nebulizer.
[0203] Compositions suitable for buccal or sublingual administration include tablets, lozenges and pastilles, wherein the active ingredient is formulated with a carrier such as sugar, acacia, tragacanth or gelatin and glycerin. Compositions for rectal administration may conveniently be in the form of suppositories containing a conventional suppository base such as cocoa butter.
[0204] The suppository form of the compound of formula I or its pharmaceutically acceptable salt, prodrug and / or solvate can be used for vaginal, urethral and rectal administration. Such suppositories are usually composed of a mixture of substances that are solid at room temperature and melt at body temperature. The materials commonly used to make such carriers include but are not limited to cocoa butter (also referred to as cocoa butter), glycerinated gelatin, other glycerides, hydrogenated vegetable oils, polyethylene glycol mixtures of various molecular weights and fatty acid esters of polyethylene glycol. For further discussion of the suppository dosage form, see, for example, Remington's Pharmaceutical Sciences, 16th edition, Mack Publishing, Easton, PA, 1980, pp.1530-1533.
[0205] Formula I compound or its pharmaceutically acceptable salt, prodrug and / or solvate can also be coupled with a soluble polymer as a targeted drug carrier. Such polymers can include polyvinyl pyrrolidone, pyran copolymer, polyhydroxypropyl methacrylamide-phenol, polyhydroxyethyl asparagine-phenol or polyethylene oxide-polylysine substituted with palmitoyl. In addition, Formula I compound or its pharmaceutically acceptable salt, prodrug and / or solvate can be coupled with a class of biodegradable polymers that can be used to achieve controlled drug release, such as polylactic acid, polyglycolic acid, copolymers of polylactic acid and polyglycolic acid, poly-ε-caprolactone, polyhydroxybutyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates, and crosslinked or amphiphilic block copolymers of hydrogels.
[0206] In one embodiment, the compound of formula I or its pharmaceutically acceptable salt, prodrug and / or solvate can be coupled with a viral vector, a non-viral vector or other vector. The viral vector may include a retrovirus, a lentivirus, an adenovirus, a herpes virus, a poxvirus, an alphavirus, a vaccinia virus or an adeno-associated virus. The non-viral vector may include nanoparticles, cationic lipids, cationic polymers, metal nanoparticles, nanorods, liposomes, micelles, microvesicles, cell penetrating peptides or fat globules. The nanoparticles may include silicon dioxide, lipids, carbohydrates or other pharmaceutically acceptable polymers.
[0207] In one embodiment, depending on the mode of administration, the pharmaceutical composition will contain 0.05% to about 99% by weight or about 0.10% to about 70% by weight of the active ingredient (compound of Formula I) and about 1% to about 99.95% by weight or about 30% to about 99.90% by weight of one or more pharmaceutically acceptable carriers, all weight percentages being based on the total weight of the composition.
[0208] In one embodiment, the pharmaceutical composition is formulated for oral administration. In one embodiment, the pharmaceutical composition is formulated for oral administration and comprises about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, or about 500 mg of a compound of Formula I or a pharmaceutically acceptable salt, prodrug, and / or solvate thereof.
[0209] In one embodiment, the compound of formula I or its pharmaceutically acceptable salt, prodrug and / or solvate is administered simultaneously or sequentially with another therapeutic agent in separate unit dosage forms, or is administered together in a single unit dosage form. Therefore, the application provides a single unit dosage form, which comprises a compound of formula I or its pharmaceutically acceptable salt, prodrug and / or solvate, another therapeutic agent and a pharmaceutically acceptable carrier.
[0210] In an embodiment, the composition is formulated for parenteral administration.In one embodiment, the composition is formulated for transdermal administration.
[0211] The compound of formula I or its pharmaceutically acceptable salt, prodrug and / or solvate can be used alone to treat acute pain, urinary chronic pelvic pain syndrome (UCPPS) or bladder inflammation, or in combination with other drugs known to be useful for treating acute pain, urinary chronic pelvic pain syndrome (UCPPS) or bladder inflammation.
[0212] One embodiment is to administer or use the other known drug for the treatment of acute pain, urological chronic pelvic pain syndrome (UCPPS) or bladder inflammation according to a known treatment regimen of the other known drug.
[0213] In one embodiment, the compound of formula I is in the form of a pharmaceutically acceptable solvate. In one embodiment, the compound of formula I is in neutral form (i.e., not a salt). In one embodiment, the compound of formula I is a prodrug of the compound of formula I. In one embodiment, the compound of formula I is a solvate of a prodrug of the compound of formula I.
[0214] IV. Preparation method
[0215] The compounds of formula I can be prepared by various synthetic methods. The selection of specific methods is within the capabilities of those skilled in the art. Certain raw materials can be obtained from commercial chemical sources. Other raw materials, such as the raw materials described below, can be easily prepared from available precursors using direct conversions known in the art.
[0216] The compounds of formula I can generally be prepared by the process shown in the following scheme. It should be noted by those skilled in the art that many of the reactions described in the following schemes are sensitive to oxygen and water, so if necessary, those skilled in the art know to carry out the reactions under an anhydrous inert atmosphere. The reaction temperatures and times are for illustrative purposes only and can be changed to optimize the yield according to the understanding of those skilled in the art.
[0217] Thus, compounds of formula I are prepared as shown in Scheme 1. Thus, under suitable coupling conditions, a compound of formula A (ketoprofen) is coupled with a compound of formula B (hydroxybenzamide) using a suitable coupling agent (e.g., dicyclohexylcarbodiimide (DCC) and hydroxybenzotriazole (HOBt)) in a suitable solvent (e.g., dimethylformamide) to provide a compound of formula C. The compound of formula C is then thionated with a suitable thionating agent (e.g., Lawesson's reagent) in a suitable solvent (e.g., anhydrous benzene) to provide a compound of formula I.
[0218]
[0219] The compounds of formula I may also be prepared by methods known in the art, for example by methods disclosed in US Pat. No. 8,541,398 and / or US Pat. No. 7,910,568. Example
[0220] The following non-limiting examples illustrate the present application:
[0221] Example 1: Synthesis of compounds of formula I
[0222]
[0223] Step 1: Synthesis of 2-(4-oxophenyl)-phenylpropionic acid 4-carbamoylphenyl ester
[0224] To a solution of 1 (ketoprofen, 3 g, 11.8 mmol) in 80 ml of dimethylformamide were added hydroxybenzotriazole (1.76 g, 13 mmol) and DCC (2.68 g, 13 mmol) and stirred at 0°C for 1 h. 4-Hydroxybenzamide (2, 2.43 g, 17.7 mmol) was added to the reaction mixture and stirred at 0°C for 1 h and at room temperature for 2 h. After filtration, the filtrate was evaporated under reduced pressure to remove the solvent. The oily residue thus obtained was dissolved in ethyl acetate; the organic layer was washed with brine, 3.5% NaHCO3 and 10% citric acid, then dried over anhydrous MgSO4, filtered and the solvent was evaporated. The crude product 3 was charged into a silica gel open column and eluted with CH2Cl2 / MeOH (9.5 / 0.5) to obtain 2-(4-oxophenyl)-phenylpropionic acid 4-carbamoylphenyl ester (3) (1.84 g, yield 42%).
[0225] Step 2: Synthesis of 2-(4-oxophenyl)-phenylpropionic acid 4-thiocarbamoylphenyl ester
[0226] 2-(4-Oxophenyl)-phenylpropionic acid 4-carbamoylphenyl ester (3) (1.84 g, 4.93 mmol) and Lawesson's reagent (2 g, 4.93 mmol) were dissolved in 100 ml of anhydrous benzene. The reactants were warmed to 60° C. and stirred for 4 h. The solvent was removed under reduced pressure. The obtained compound was purified by silica gel open column and eluted with CH2Cl2 / MeOH (9.5 / 0.5) to obtain pure compound 4 (0.45 g, yield 23%).
[0227] 1 H NMR(DMSO-d6): δ1.53(d,3H),4.25(dd,1H),7.08(d,2H),7.54-7.73(m,9H),7.90(d,2H),9.51and 9.88(s,2H,NH2). 13 C NMR(DMSO-d6): δ19.2,44.9,121.6,129.3,129.5,129.8,130.3,132.6,133 .5,137.6,137.9,138.1,141.2,153.3,154.5,156.1,163.8,172.9,199.6.
[0228] MS(EI),m / e 390(M + );
[0229] mp:114-116℃.
[0230] Biological data
[0231] Example 2: Comparative evaluation of ketoprofen and the compound of formula I in the interstitial cystitis / visceral pain syndrome mouse model
[0232] Materials and methods
[0233] Test substances and reagents
[0234] The compound of formula I (ATB-352) was provided by Antibe Therapeutics, Inc., and ketoprofen was purchased from Sigma-Aldrich (Oakville, ON, Canada). A suspension of the compound of formula I (4.6, 15, 46, or 77 mg kg -1 ) and equimolar doses of ketoprofen suspension (3, 10, 30, or 50 mg kg -1) was freshly prepared in 0.5% CMC (Cromoline Quimica Fina Ltd., Diadema, SP, Brazil). Cyclophosphamide, carbachol, KCl, and CMC were purchased from Sigma Chemical Co. (St. Louis, MO). Isoflurane was purchased from Prod Quimicos Farm Ltda. (Itapira / SP, Brazil).
[0235] animal
[0236] Experiments were performed with male C57BL / 6 SPF mice (6–10 weeks old) obtained from the Animal Care Facility of the University of São Paulo Medical School, Brazil. Mice were randomly assigned to different treatment groups (n = 5–7 per group). Groups of 5 or fewer mice were housed in Perspex cages under standard control conditions (22°C; 12 / 12 h light / dark cycle) with free access to food (Nuvilab CR-1, Quimtia S / A, Brazil) and filtered tap water. This study was conducted in accordance with the guidelines of the Brazilian Committee for the Regulation of Animal Experimentation (CONCEA) guidelines and in accordance with the Animal Welfare Act. All experimental protocols were approved by the local ethics committee (CEUA—ICB; protocol number 2055050819). According to the laboratory internal regulations, euthanasia was performed in case of severe discomfort related to the investigational drugs during the experiments.
[0237] Cystitis induction and experimental design
[0238] Cystitis was induced by a single intraperitoneal injection of cyclophosphamide CYP (300 mg kg -1 ; Oliveira et al., 2018), while the control group was injected intraperitoneally with normal saline (10 ml kg -1 ). 21 hours after CYP injection, mice were orally administered with vehicle, ketoprofen, or a compound of Formula I. This included a series of doses of ketoprofen (3, 10, 30, or 50 mg kg -1 ), compounds of formula I (4.6, 15, 46 or 77 mg kg -1 ) or vehicle (0.5% carboxymethyl cellulose; 0.5% CMC). The drug was dissolved in 0.5% CMC at a concentration of 10 ml kg -1 Table 1 lists the treatment groups.
[0239] Table 1
[0240] Groups and therapies dose N Brine + 0.5% CMC <![CDATA[10ml kg -1 ; Oral]]> 6 Cystitis + 0.5% CMC 10ml kg-1; Oral 7 Cystitis + compound of formula I <![CDATA[4.6mg kg -1 ; Oral]]> 6 Cystitis + compound of formula I <![CDATA[15mg kg -1 ; Oral]]> 5 Cystitis + compound of formula I <![CDATA[46mg kg -1 ; Oral]]> 6 Cystitis + compound of formula I <![CDATA[77mg kg -1 ; Oral]]> 6 Cystitis + Ketoprofen <![CDATA[3mg kg -1 ; Oral]]> 5 Cystitis + Ketoprofen <![CDATA[10mg kg -1 ; Oral]]> 5 Cystitis + Ketoprofen <![CDATA[30mg kg -1 ; Oral]]> 5 Cystitis + Ketoprofen <![CDATA[50mg kg -1 ; Oral]]> 6
[0241] Mechanical allodynia measured by electronic von Frey test
[0242] Mice were individually placed in a clear Perspex testing chamber (11 cm x 9.5 cm x 18 cm) on an elevated wire grid platform (0.5 cm 2 Grid) to allow for adequate acclimation (approximately 1 h). As previously described (Costa et al., 2020), the cells were placed on an electronic von Frey instrument (Insight Inc., Mechanical sensitivity was assessed with the help of Preto, SP, Brazil, with 5–7 mice per group. A pressure transducer connected to a digital force gauge (Insight Ltd, Preto / SP, Brazil), the pressure that produces force is applied to the lower abdomen (pelvic region between the urethra and anus) near the bladder. Abdominal retraction from the probe (mechanical allodynia) is considered a positive response to the stimulus and is recorded in grams (g). The stimulus is applied twice, with an interval of at least 5 to 10 seconds between stimuli, and the mean value (g) of these positive responses is recorded as the abdominal retraction threshold (mechanical allodynia) and expressed as the area under the curve (AUC) at multiple time points (21-24 hours after injection of CYP). All mechanical sensitivity tests were performed in a blinded manner. The reaction threshold data were analyzed by analysis of variance (ANOVA), followed by Tukey post hoc test. All mice were anesthetized with an overdose of isoflurane and then euthanized by cervical dislocation.
[0243] Evaluation of ketoprofen compared with ATB-352 in the treatment of gastric lesions in IC / BPS mice.
[0244] As observed in a previous study (Costa et al., 2020), the compound of formula I (77 mg kg -1 , oral) and high equimolar doses of ketoprofen (50 mg kg -1 , oral) systemic treatment to induce hemorrhagic lesions in the gastric mucosa. Briefly, mice from different experimental groups were euthanized by cervical dislocation under isoflurane anesthesia, and the stomach was removed, opened along the lesser curvature, gently rinsed with saline, and then photographed with a digital camera (Samsung Galaxy S20, Campinas / SP, Brazil). The area of hemorrhagic gastric lesions (mm) was measured under blinded conditions using computer planimetry software (ImageJ, Maryland, USA). 2 ).
[0245] In vitro bladder function test
[0246] After 24 hours, mice with CYP-induced cystitis were euthanized and the bladders were immediately transferred to a culture dish. Adipose tissue was carefully removed as described by Calmasini et al., 2021. The bladder was divided into two longitudinal strips and placed in an isolated organ waterbath system (Panlab Harvard, Massachusetts, USA) containing Krebs Henseleit solution at 37°C (pH 7.4, O2 / CO2 9 / 5v / v) and a static tension of 5mN. The tissue was allowed to stabilize for 1 hour, during which the waterbath solution was changed every 15min. Isometric force was recorded using a PowerLab 8 / 30 data acquisition system (SoftwareChart, version 6.0, ADInstrument, Milford, MA, USA).
[0247] The bladder response to a single concentration of KCl (80 mM) or to cumulative increasing concentrations of carbachol (10 -9 Up to 10 -5 ) of the control group (untreated interstitial bladder animals (IC) and two CYP groups treated with test drugs (ketoprofen and compound of formula I)).
[0248] Statistical analysis
[0249] These analyses were performed using GraphPad Version 6.0 (GraphPad Software, San Diego, USA). Data were analyzed by one-way analysis of variance (ANOVA) and Tukey post hoc test. All results are expressed as mean ± standard error of the mean (SEM), and the significance level is set at *P < 0.05.
[0250] result
[0251] Ketoprofen-based H2S donor (ATB-352) exhibits superior antihyperalgesic effects in a mouse model of interstitial cystitis / visceral (bladder) pain syndrome
[0252] Figure 1 The results showed that injection of CYP significantly reduced the pain threshold (expressed as AUC) in the pelvic region of mice orally administered with 0.5% CMC compared to the control group injected with normal saline. In this IC / BPS mouse model, the lowest equimolar dose of the compound of formula I or ketoprofen had no anti-hyperalgesic effect on the reduced withdrawal threshold. At higher doses, the compound of formula I reduced cyclophosphamide-induced abdominal mechanical allodynia in a dose-dependent manner. At a dose of 10 mg kg-1 and 30 mg kg -1 Rather than 50 mg kg -1 Ketoprofen significantly reversed CPY-induced abdominal mechanical allodynia in IC / BPS mice when compared to the control group of IC / BPS mice treated with 0.5% CMC vehicle. The use of medium and high equimolar doses of the compound of Formula I (15, 46 and 77 mg kg -1 ) detected significant dose-dependent differences in the response to mechanical allodynia. In addition, the highest equimolar dose (77 mg kg -1 ) of the compound of formula I enhanced the analgesic effect (P<0.001; Figure 1 ).
[0253] ATB-352 inhibits ketoprofen-induced gastric mucosal injury
[0254] like Figure 2 As shown, high doses of ketoprofen (50 mg kg -1 Oral administration of systemic treatment to mice resulted in the development of numerous lesions in the stomach of the animals within 3 hours ( Figure 2 (Panel D, fourth picture from the left)), while an equimolar dose of the compound of formula I (77 mg kg -1 ) or vehicle treatment of mice did not result in this situation (Panels B and C, the second and third pictures from the left, respectively).
[0255] Figure 2 Groups A to C (the first, second, third and fourth pictures from the left, respectively) show pictures of gastric mucosa of mice treated with vehicle, IC / BPS mice treated with 0.5% CMC, IC / BPS mice treated with a high dose of the compound of Formula I, and IC / BPS mice treated with a high dose of ketoprofen. Groups A, B and C (the first, second and third pictures from the left, respectively) show normal gastric mucosa, and Group D (the fourth picture from the left) shows a large area of bleeding gastric ulcer.
[0256] The compound of formula I is superior to ketoprofen in improving CYP-induced bladder dysfunction in the IC / BPS mouse model
[0257] In the control CYP bladder strips, the reduced contractility to KCl (80 mM) was significantly different from that in the vehicle-treated group ( Figure 3 A) However, compared with the control group, the -1 and 46 mg kg -1 The reduced contractile response of CYP bladder strips to KCl in mice treated with the compound of formula I ( Figure 3A) significantly and dose-dependently increased (p < 0.05), while ketoprofen at an equimolar dose did not. At high doses, both the compound of formula I (77 mg kg -1 ) or ketoprofen (50 mg kg -1 ) did not significantly improve the reduced bladder contractility in response to KCl in IC / BPS mice.
[0258] Likewise, in mice treated with high doses of the compound of formula I and ketoprofen, the maximum contractile response (E max ) were significantly increased, whereas there was no significant increase in mice treated with low doses of either compound ( Figure 3 B) At moderate doses of ketoprofen (10 mg kg -1 and 30 mg kg -1 ) but not the compound of formula I, the maximum contractile response (E max ) was significantly reversed ( Figure 3 B).
[0259] in conclusion
[0260] The data from this study demonstrate that injection of CYPs into C57Bl / 6 mice produces bladder inflammation and associated visceral / pelvic pain, in addition to reduced functional contractility in an isolated bladder phenotype. In a CYP-induced IC / BPS-like model, these functional and behavioral changes were significantly reduced following treatment with moderate and high doses of the compound of Formula I, and to a lesser extent with the parent molecule (ketoprofen).
[0261] Based on the increased beneficial effects of the compound of formula I on the abdominal hyperalgesic state and reduced bladder contractile responses compared to ketoprofen in the CYP-induced IC / BPS model, we conclude that the compound of formula I is more potent than ketoprofen when administered orally as a single dose.
[0262] In addition, it was found that the compounds of formula I can reduce the gastrointestinal toxicity of ketoprofen while improving the analgesic / anesthetic effect. These data together suggest that H2S donor drugs (compounds of formula I) may have significant potential to improve or treat urothelial health and symptoms (including visceral pain (bladder inflammation)) in IC / BPS patients.
[0263] Although the present application has been described by reference to examples, it should be understood that the scope of the claims should not be limited by the embodiments described in the examples, but should be given the broadest interpretation consistent with the entire specification.
[0264] All publications, patents, and patent applications are incorporated herein by reference in their entirety to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated herein by reference in its entirety. When a term in this application is found to have a different definition in a document incorporated herein by reference, the definition provided herein will serve as the definition for that term.
[0265] Full citations of documents cited in the specification
[0266] Many publications are cited herein. Full citations for these references are provided below. Each of these documents is incorporated herein by reference in its entirety to the same extent as if each individual document was specifically and individually indicated to be incorporated herein by reference.
[0267] Bindu S, Mazumder S, and Bandyopadhyay U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: a current perspective. BiochemPharmacol 180:114147, 2020
[0268] Calmasini FB, Alexandre EC, Oliveira MG, Silva FH, Soares AG, Costa SKP, Antunes E. Lipopolysaccharide reduces urethral smooth muscle contractility via cyclooxygenase activation. J Physiol Biochem. 2021May 21. doi:10.1007 / s13105-021-00819-8.
[0269] Clemens JQ, Mullins C, Acherman et al. 2019. Urologic chronic pelvic pain syndrome: insights from the MAPP Research Network. Nature Reviews Urology volume 16, pages187–200.2.
[0270] Costa SK,Muscara M,Allain T,Dallazen J,Santos LG,Buret AG,Vaughan D,Fowler CJ,De Nucci GN,Wallace JL.Enhanced analgesic effects and GI safety ofa novel hydrogen sulfide-releasing anti-inflammatory drug(ATB-352):Arole forendogenous cannabinoids.Antioxid Redox Signal.2020Feb 16.doi:10.1089 / ars.2019.7884.
[0271] de Oliveira MG,Calmasini FB,Alexandre EC,De Nucci G,Mónica FZ,AntunesE(2016).Activation of soluble guanylyl cyclase by BAY 58-2667improves bladderfunction in cyclophosphamide-induced cystitis in mice.Am J Physiol RenalPhysiol.311:F85-F93.
[0272] Glowacka et al.,Microbiome Profile and Molecular Pathways Alterationsin Gastrointestinal Tract by Hydrogen Sulfide-Releasing Nonsteroidal Anti-lnflammatory Drug(ATB-352):lnsight into Possible Safer PolypharmacyANTIOXIDANTS&REDOX SIGNALING Volume 36,(4-6),2022
[0273] Gugliandolo E,Fusco R,D'Amico R,Militi A,Oteri G,Wallace JL,Di PaolaR,and Cuzzocrea S.Antiinflammatory effect of ATB-352,a H2S-releasingketoprofen derivative,on lipopolysaccharide-induced periodontitis inrats.Pharmacol Res 132:220-231,2018.
[0274] Lasheen NN,Elayat WM,Elrefai MFM,Zaki WS,Ahmed EH,El Sheikh RMN,AboRaya DSA,and Gad FRS.Possible role of garlic oil in ameliorating renal injuryafter liverischemia / reperfusion in rats.J Physiol Pharmacol 70:765-778,2019.
[0275] Malykhina AP.Neural mechanisms of pelvic organ cross-sensitization.Neuroscience.2007;149:660–672.https: / / doi.org / 10.1016 / j.neuroscience.2007.07.053 PMID:17920206.
[0276] Masaki et al.(2020)Nitric Oxide 1(104-105):44-50,,,,,.
[0277] Okifuji A,Hare BD.The association between chronic pain and obesity.JPain Res.2015;8:399–408.
[0278] Sun H,Yang J,Shi Y,Wang Y,Li C,and Zhu M.Hydrogen sulfide in thenucleus tractussolitarüregulates gastric acid secretion in rats.J PhysiolPharmacol 71:1-5,2020.
[0279] Russell RI.Non-steroidal anti-inflammatory drugs and gastrointestinaldamage—problemsand solutions.Postgrad Med J 77:82-88,2001.
[0280] Wallace JL,Ianaro A,and de Nucci G.Gaseous mediators ingastrointestinal mucosaldefense and injury.Dig Dis Sci 62:2223-2230,2017.
[0281] Winfield RD,Reese S,Bochicchio K,Mazuski JE,Bochicchio GV.Obesity andthe risk forsurgical site infection in abdominal surgery.Am Surg.2016;82:331-336.
Claims
1. A method of treating pain associated with urinary chronic pelvic pain syndrome (UCPPS) in an individual in need thereof, comprising administering to the individual an effective amount of a compound of formula I, or a pharmaceutically acceptable salt, prodrug and / or solvate thereof.
2. The method of claim 1, wherein the pain associated with UCPPS is selected from one or more of the following: visceral pain, neuropathic pain, neuralgia, allodynia, causalgia, hyperalgesia, hyperesthesia, hyperalgesia, and neuropathy secondary to surgery.
3. The method of claim 2, wherein the pain associated with UCPPS is UCPPS-associated allodynia.
4. The method of claim 2, wherein the pain associated with UCPPS is UCPPS associated hyperalgesia.
5. The method of claim 2, wherein the pain associated with UCPPS is visceral pain associated with UCPPS.
6. The method according to any one of claims 1 to 5, wherein the pain associated with UCPPS is acute and / or chronic pain associated with UCPPS.
7. The method of claim 6, wherein the pain associated with UCPPS is chronic pain associated with UCPPS.
8. The method of claim 6, wherein the pain associated with UCPPS is acute pain associated with UCPPS.
9. The method of claim 8, wherein the acute pain associated with UCPPS is a temporary increase or flare-up of pain associated with UCPPS.
10. The method of claim 8 or claim 9, wherein the acute pain lasts less than about 14 days, less than about 12 days, less than about 10 days, less than about 7 days, less than about 5 days, or less than 3 days from the onset of the acute pain.
11. The method of claim 8 or claim 9, wherein the acute pain lasts from about 1 day to about 14 days, from about 1 day to about 12 days, from about 1 day to about 10 days, from about 1 day to about 7 days, from about 1 day to about 5 days, from about 1 day to about 3 days, or from about 3 days to 14 days, from about 3 days to about 10 days, from about 3 days to 7 days, or from about 5 days to about 10 days.
12. The method according to any one of claims 8 to 11, wherein the acute pain occurs intermittently, lasts for more than 3 months, or lasts for more than 6 months.
13. The method of any one of claims 1 to 12, wherein the pain associated with UCPPS is selected from one or more of the following: lower abdominal (pelvic) pain, bladder pain, suprapubic pain, vaginal pain, pain in the penis, testicles, scrotum or perineum, urethral pain, dyspareunia or pain, increased pressure or discomfort with bladder filling.
14. The method of any one of claims 1 to 12, wherein the UCPPS is interstitial cystitis / bladder pain syndrome (IC / BPS).
15. The method of claim 14, wherein the UCPPS is interstitial cystitis (IC).
16. The method of claim 14, wherein the UCPPS is bladder pain syndrome (BPS).
17. The method of any one of claims 1 to 12, wherein the UCPPS is chronic prostatitis / chronic pelvic pain syndrome (CP / CPPS).
18. A method of treating urinary chronic pelvic pain syndrome (UCPPS) in a subject in need thereof, comprising administering to the subject an effective amount of a compound of formula I, or a pharmaceutically acceptable salt, prodrug and / or solvate thereof.
19. The method of claim 18, wherein the UCPPS is interstitial cystitis / bladder pain syndrome (IC / BPS).
20. The method of claim 19, wherein the UCPPS is interstitial cystitis (IC).
21. The method of claim 19, wherein the UCPPS is bladder pain syndrome (BPS).
22. The method of claim 18, wherein the UCPPS is chronic prostatitis / chronic pelvic pain syndrome (CP / CPPS).
23. A method of treating one or more symptoms associated with urinary chronic pelvic pain syndrome (UCPPS) in a subject in need thereof, comprising administering to the subject an effective amount of a compound of formula I, or a pharmaceutically acceptable salt, prodrug and / or solvate thereof.
24. The method of claim 23, wherein the UCPPS is interstitial cystitis / bladder pain syndrome (IC / BPS).
25. The method of claim 24, wherein the UCPPS is interstitial cystitis (IC).
26. The method of claim 24, wherein the UCPPS is bladder pain syndrome (BPS).
27. The method of claim 23, wherein the UCPPS is chronic prostatitis / chronic pelvic pain syndrome (CP / CPPS).
28. The method of any one of claims 23 to 27, wherein the one or more symptoms are selected from the group consisting of irritative urinary symptoms, urinary frequency, urinary urgency, nocturia, urinary incontinence, and suprapubic or pelvic pain associated with and relieved by urination.
29. A method of treating bladder inflammation in a subject in need thereof, comprising administering to the subject an effective amount of a compound of formula I, or a pharmaceutically acceptable salt, prodrug and / or solvate thereof.
30. The method of claim 29, wherein the bladder inflammation is associated with urological chronic pelvic pain syndrome (UCPPS).
31. The method of claim 30, wherein the UCPPS is interstitial cystitis / bladder pain syndrome (IC / BPS).
32. The method of claim 31 , wherein the UCPPS is interstitial cystitis (IC).
33. The method of claim 31, wherein the UCPPS is bladder pain syndrome (BPS).
34. The method of claim 30, wherein the UCPPS is chronic prostatitis / chronic pelvic pain syndrome (CP / CPPS).
35. A method of increasing bladder contraction and relaxation in a subject in need thereof, comprising administering to the subject an effective amount of a compound of formula I, or a pharmaceutically acceptable salt, prodrug and / or solvate thereof.
36. The method of claim 35, wherein the subject suffers from urological chronic pelvic pain syndrome (UCPPS).
37. The method of claim 35, wherein the subject suffers from interstitial cystitis / bladder pain syndrome (IC / BPS).
38. The method of claim 35, wherein the subject suffers from chronic prostatitis / chronic pelvic pain syndrome (CP / CPPS).
39. A method of treating acute pain in a subject in need thereof, comprising administering to the subject an effective amount of a compound of formula I, or a pharmaceutically acceptable salt, prodrug and / or solvate thereof.
40. The method of claim 39, wherein the acute pain is a temporary exacerbation or flare-up.
41. The method of claim 39 or claim 40, wherein the acute pain is pain that is expected to resolve in 14 days or less.
42. The method of any one of claims 39 to 41, wherein the acute pain occurs intermittently and lasts for more than 3 months or more than 6 months.
43. The method of claim 39, wherein the acute pain is postoperative pain resulting from abdominal and / or pelvic surgery.
44. The method according to any one of claims 1 to 43, wherein the compound of formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof is orally administered at a dosage of 50 mg to about 500 mg per day for an adult.
45. The method of claim 44, wherein the compound of Formula I, or a pharmaceutically acceptable salt, prodrug and / or solvate thereof, is administered at an oral dose of about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 250 mg, about 275 mg, about 300 mg, about 325 mg, about 350 mg, about 375 mg, about 400 mg, about 425 mg, about 450 mg, about 475 mg, or about 500 mg per day.
46. The method of claim 44, wherein the compound of formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof is administered at an oral dose of about 200 mg per day to about 400 mg per day or about 250 mg per day to about 325 mg per day.
47. The method of any one of claims 1 to 46, wherein the compound of Formula I, or a pharmaceutically acceptable salt, prodrug and / or solvate thereof, is administered for 1 day to 14 days, 2 days to 10 days, 2 days to 9 days, 2 days to 8 days, 2 days to 7 days, 2 days to 6 days, or 3 days to 5 days.
48. The method according to any one of claims 1 to 44, wherein the compound of formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof is administered at an oral dose of about 400 mg per day or about 500 mg per day, and the compound of formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof is administered for 1 day.
49. The method of any one of claims 1 to 44, wherein the compound of Formula I, or a pharmaceutically acceptable salt, prodrug and / or solvate thereof, is administered at an oral dose of about 200 mg per day to about 400 mg per day, about 250 mg per day to about 350 mg per day, or about 250 mg per day to about 325 mg per day, and the compound of Formula I, or a pharmaceutically acceptable salt, prodrug and / or solvate thereof, is administered for 1 day to 10 days, 1 day to 8 days, 1 day to 7 days, 1 day to 5 days, 2 days to 7 days, 3 days to 7 days, 4 days to 7 days, 5 days to 7 days, 6 days to 7 days, 2 days to 5 days, 3 days to 5 days, 4 days to 5 days, 2 days, 3 days, 4 days, 5 days, 6 days or 7 days.
50. The method according to any one of claims 1 to 49, wherein the compound of formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof is formulated into a pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt, prodrug and / or solvate thereof and one or more pharmaceutically acceptable carriers.
